---
title: How to Prepare a Regulatory-Ready Nitrosamine Risk Assessment
description: Based on 2,000+ assessments, learn how to identify risk assessment gaps, justify conclusions, and meet nitrosamine regulatory expectations.
image: https://blog.pqegroup.com/hubfs/Nitrosamine%20Risk%20Assessment_Blog.webp
---

[![Logo PQE Group - azzurro - 2024](https://blog.pqegroup.com/hs-fs/hubfs/Logo%20PQE%20Group%20-%20azzurro%20-%202024.png?width=2000&height=721&name=Logo%20PQE%20Group%20-%20azzurro%20-%202024.png "Logo PQE Group - azzurro - 2024")](https://www2.pqegroup.com)

- [Home](https://www2.pqegroup.com/)
- [Industry](https://www2.pqegroup.com/industry/) 
    - [Pharma & API](https://www2.pqegroup.com/pharma-api/)
    - [Medical Device](https://www2.pqegroup.com/medical-device/)
    - [Biotech](https://www2.pqegroup.com/biotech/)
    - [Startup](https://www2.pqegroup.com/startup/)
    - [Veterinary](https://www2.pqegroup.com/veterinary/)
- [Services](https://www2.pqegroup.com/services/) 
    - [Data Integrity](https://www2.pqegroup.com/data-integrity/)
    - [Digital Governance](https://www2.pqegroup.com/digital-governance/)
    - [Engineering](https://www2.pqegroup.com/engineering/)
    - [Commissioning, Qualification and Validation (CQV)](https://www2.pqegroup.com/commissioning-qualification-validation/)
    - [Quality Compliance](https://www2.pqegroup.com/quality-compliance/)
    - [Laboratory Excellence](https://www2.pqegroup.com/laboratory-excellence/)
    - [Regulatory Affairs](https://www2.pqegroup.com/regulatory-affairs/)
    - [Audits](https://www2.pqegroup.com/audits/)
    - [Training](https://www2.pqegroup.com/training/)
    - [Clinical Research](https://www2.pqegroup.com/clinical-research-services/)
    - [Pharmacovigilance](https://www2.pqegroup.com/pharmacovigilance/)
- About 
    - [About Us](https://www2.pqegroup.com/about/)
    - [ESG](https://www2.pqegroup.com/about/csr/)
    - [Women in STEM](https://www2.pqegroup.com/about/women-in-stem/)
- Resources 
    - [News & Press](https://www2.pqegroup.com/news/)
    - [Webinars](https://www2.pqegroup.com/webinars/)
    - [Blog](https://blog.pqegroup.com/)
- [Careers](https://www2.pqegroup.com/careers/)
- [Contact Us](https://www2.pqegroup.com/contact-us/)

![](https://blog.pqegroup.com/hubfs/blank-user.png)

Alfredo Vannini

Senior Director Quality Assurance, Operations Manager, GMP-API Auditor @PQE Group

# **How to Prepare a Regulatory-Ready Nitrosamine Risk Assessment**

[GxP Compliance](https://blog.pqegroup.com/tag/gxp-compliance)

The regulatory focus on nitrosamine impurities in the pharmaceutical industry has evolved significantly over the years. What began with concerns around compounds such as NDMA and NDEA has expanded to include excipients, packaging materials, manufacturing operations, and Nitrosamine Drug Substance-Related Impurities (NDSRIs). Today, regulatory authorities, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), expect companies to demonstrate a comprehensive understanding of all potential pathways through which nitrosamines may be introduced or formed. 

Based on PQE's experience conducting more than 2,000 risk assessments since 2019, one question continues to emerge: What makes a nitrosamine risk assessment capable of withstanding regulatory review? 

In this article, we explore some of the key considerations, common pitfalls, and lessons learned from supporting pharmaceutical companies worldwide. 

## The Challenge Is Often Greater

Than Expected One of the most common misconceptions is that a nitrosamine risk assessment can be completed using information available internally. 

In reality, building a robust assessment typically requires collecting and evaluating information from multiple sources, including API manufacturers, excipient suppliers, packaging material providers, manufacturing sites, and quality systems. Additional factors such as cleaning agents, sanitization procedures, historical deviations, potential cross-contamination events, and product stability data may also contribute to the overall risk profile. 

The challenge does not end with data collection itself. The real question is whether the information gathered is sufficiently complete, reliable, and scientifically justified to support an objective conclusion. This is where many assessments become vulnerable. 

Based on PQE's experience, one recurring observation stands out: **The absence of information should never be confused with the absence of risk.**  

Why Some Assessments Trigger Questions from Authorities 

One of the most overlooked risk factors is the tendency to justify risk reductions based on assumptions that cannot be adequately supported by scientific evidence. 

While a product may initially appear to present a limited nitrosamine risk, regulators expect companies to demonstrate **how** conclusions were reached, **what** supporting data were reviewed, and **why** specific risks were ruled out. 

A second area that frequently attracts attention is the evaluation of products containing APIs that have already been associated with nitrosamine-related concerns by health authorities. In these situations, relying exclusively on a theoretical assessment may not always be sufficient. Depending on the product and the available data, additional investigations or analytical testing of the final dosage form may be necessary to better understand how nitrosamine impurities are formed and provide a stronger scientific justification. 

Ultimately, the difference between an assessment that is smoothly accepted and one that generates clarification requests often comes down to one principle: **A complete, objective, and evidence-based assessment.** 

## When Does Additional Investigation Become Necessary?

While every product presents unique considerations, the decision should be based on a systematic evaluation of identified risks, available supporting documentation, and the overall confidence in the information collected. 

As a general principle, when the risk evaluation results in a **High or Medium risk** classification, additional investigation and analytical testing should be considered to strengthen the justification. 

Particular attention should also be given to products containing substances that have previously raised nitrosamine concerns with regulatory agencies. For these products, testing may provide an additional layer of confidence and help demonstrate that the risk has been adequately characterized and controlled. 

## What PQE Has Learned From More Than 2,000 Assessments

Since 2019, PQE has supported more than 2,000 nitrosamine risk assessments across a wide variety of products, technologies, and global markets, achieving an exceptionally high acceptance rate, with approximately **0.15% clarification requests and no rejections from regulatory authorities.** 

This experience has revealed several important lessons. 

**First, the quality of the assessment depends on the quality of the information collected.** Missing, incomplete, or unclear information should never automatically lead to a low-risk conclusion. In many cases, information gaps represent a risk factor in themselves and justify a more conservative evaluation approach.

**Second, documentation gaps often present a greater challenge than the technical evaluation itself.** Regulatory authorities expect conclusions to be supported by objective evidence and transparent scientific rationale.  

**Third, products associated with known nitrosamine concerns require heightened scrutiny.** One of the most frequently overlooked aspects is the need to adequately assess products containing APIs already identified by health authorities as having an elevated nitrosamine risk profile. In these cases, additional confirmatory activities may be warranted to support the conclusions reached. 

These lessons translate into tangible business outcomes. In one recent engagement, PQE supported a Marketing Authorization Holder whose product had been identified as potentially at risk for nitrosamine impurities. Following a comprehensive risk evaluation, PQE recommended additional actions and confirmatory testing to strengthen the assessment package. The recommendations were implemented, the product was further investigated, and the resulting data demonstrated impurity levels below the applicable acceptance limits. As a result, the authorities accepted the assessment, the batches were approved, and the product was allowed to proceed to market. 

While every product presents unique challenges, this example highlights an important principle: a robust, evidence-based assessment helps companies make informed decisions, avoid unnecessary delays, and maintain confidence in product supply. 

## Why Companies Choose PQE for their Nitrosamine Risk Assessment

Life science organizations looking for specialized nitrosamine risk assessment services need a partner with scientific expertise, regulatory understanding, and practical experience. Over the years, PQE has developed dedicated tools and methodologies designed to support a strong evaluation process. These approaches help companies identify potential concerns, prioritize areas requiring further investigation, and build documentation packages capable of supporting regulatory expectations. 

Nitrosamine risk assessment requires much more than regulatory knowledge alone. What differentiates PQE is the ability to identify vulnerabilities that may otherwise be overlooked. 

PQE brings together: 

- Extensive experience gained from more than 2,000 real-world evaluations
- A structured risk assessment methodology
- Dedicated tools developed to support objective and consistent decision-making
- Expertise spanning APIs, excipients, manufacturing processes, packaging systems, and quality operations
- A risk-based approach designed to support defensible conclusions
- Practical understanding of what regulators expect

 Most importantly, PQE helps companies transform nitrosamine risk assessment from a compliance obligation into a strategic, evidence-based process that supports confident regulatory decisions and uninterrupted product supply.

![Nitrosamine Risk Assessment\_Blog](https://blog.pqegroup.com/hs-fs/hubfs/Nitrosamine%20Risk%20Assessment_Blog.webp?width=2000&name=Nitrosamine%20Risk%20Assessment_Blog.webp)

## Want to know more?

Leverage our experience from 2,000+ nitrosamine risk assessments to identify risks, address gaps, and strengthen compliance.

 

[Connect with us](https://www2.pqegroup.com/contact-us/)

#### More on this topic

[GxP Compliance ![Your AI-Enabled Device Will Change. Is Your Regulatory Strategy Ready?](https://blog.pqegroup.com/hubfs/AI-Enabled%20Device_Blog.webp)](https://blog.pqegroup.com/gxp-compliance/your-ai-enabled-device-will-change.-is-your-regulatory-strategy-ready)

 10 Nov 2026

## [Your AI-Enabled Device Will Change. Is Your Regulatory Strategy Ready? AI is changing medical devices and so are the regulatory challenges. Is your strategy ready?](https://blog.pqegroup.com/gxp-compliance/your-ai-enabled-device-will-change.-is-your-regulatory-strategy-ready)

[GxP Compliance ![The FDA Guide to AI in Drug Development](https://blog.pqegroup.com/hubfs/FDA%20guidance%20on%20AI_Blog.webp)](https://blog.pqegroup.com/gxp-compliance/the-fda-guide-to-ai-in-drug-development)

 30 Jun 2026

## [The FDA Guide to AI in Drug Development Read more about how the FDA is redefining AI in drug development from regulatory guidance to compliance expectations.](https://blog.pqegroup.com/gxp-compliance/the-fda-guide-to-ai-in-drug-development)

[GxP Compliance ![Why Your Path to Sustainability Should Start With ESG](https://blog.pqegroup.com/hubfs/Path%20to%20Sustainability%20ESG_Blog-2.webp)](https://blog.pqegroup.com/gxp-compliance/why-your-path-to-sustainability-should-start-with-environmental-social-and-governance-esg)

 09 Jun 2026

## [Why Your Path to Sustainability Should Start With ESG ESG is reshaping the pharmaceutical industry, discover how new regulations are driving transparency, compliance, and sustainable growth.](https://blog.pqegroup.com/gxp-compliance/why-your-path-to-sustainability-should-start-with-environmental-social-and-governance-esg)

![new PQE logo white tagline](https://blog.pqegroup.com/hubfs/new%20PQE%20logo%20white%20tagline.png)

ISO 9001 Certified compliance services provider since 1998.

 

![Logo ISO 9001](https://blog.pqegroup.com/hs-fs/hubfs/Logo%20ISO%209001.png?width=125&name=Logo%20ISO%209001.png)

 

- Discover PQE 
    - [Work with PQE](https://www2.pqegroup.com/careers/)
    - [Locations](https://www2.pqegroup.com/contact-us/#locations)
    - [About](https://www2.pqegroup.com/about/)
    - [Blog](https://blog.pqegroup.com/)

- Useful Links 
    - [Privacy Notice](https://www2.pqegroup.com/privacy-notice/)
    - [Cookie Policy](https://www2.pqegroup.com/cookie-policy/)
    - [Model of Organization](https://www2.pqegroup.com/model-of-organization/)
    - [Ethical Code](https://www2.pqegroup.com/ethical-code/)

English

CHANGE LANGUAGE

Copyright **2024** | Proudly powered by **PQE Group Creative Team**

[LinkedIn](https://www.linkedin.com/company/pqe-group) [![twitter](https://blog.pqegroup.com/hubfs/twitter-w.png) Twitter](https://twitter.com/PQEGroup) [Facebook](https://www.facebook.com/PQEGroup/) [Instagram](https://www.instagram.com/lifeatpqe) [YouTube](https://www.youtube.com/c/PQEGroup) [Xing](https://www.xing.com/pages/pqegroup)